Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares in the U.S. District Court for the Southern District of California (No: 3:26-cv-04643).

Investors, who purchased a significant amount of Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 13, 2025 and May 14, 2026, in excess of $100,000 have certain options and there are short and strict deadlines running. Deadline: October 31, 2026. NASDAQ: AARD investors should contact the Shareholders Foundation at [e-mail] or call +1(858) 779 - 1554.

On August 14, 2024, an investor in NASDAQ: AARD shares filed lawsuit against Aardvark Therapeutics, Inc. The plaintiff alleges that the Offering Documents that were filed in the Company’s February 13, 2025 initial public offering (“IPO”) and that between February 13, 2025 and May 14, 2026 the Defendants made false and/or misleading statements and/or failed to disclose that ARD-101 was less safe than the Defendants had led investors to believe, that accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated, and that as a result, the Defendants’ public statements were materially false and misleading at all relevant times.

Those who purchased NASDAQ: AARD shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.